Related Experiment Video

Updated: Aug 24, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Monoclonal antibodies against TRAIL

Nina-Beate Liabakk1, Terje Espevik

  • 1Institute of Cancer Research and Molecular Medicine Norwegian University of Science and Technology, N-7489 Trondheim, Norway.

Vitamins and Hormones
|April 28, 2004
PubMed

Insights

Monoclonal antibodies targeting tumor necrosis factor related apoptosis inducing ligand (TRAIL) are valuable tools for cancer therapy and arthritis research. These antibodies aid in detecting soluble TRAIL and understanding its physiological roles in health and disease.

Area of Science:

  • Immunology
  • Oncology
  • Rheumatology

Background:

  • Tumor necrosis factor related apoptosis inducing ligand (TRAIL) is a cytokine with potential therapeutic applications in cancer due to its selective cancer cell-killing properties.
  • Emerging research indicates TRAIL's role in inhibiting arthritis development.
  • Monoclonal antibodies against TRAIL have been developed to investigate its functions in various biological contexts.

Purpose of the Study:

  • To provide a comprehensive overview of available monoclonal antibodies against TRAIL.
  • To highlight the utility of these antibodies in immunological techniques, particularly immunoassays for soluble TRAIL detection.
  • To discuss the physiological significance of findings derived from TRAIL antibody research.

Main Methods:

  • Review of published and commercially available monoclonal antibodies against TRAIL.
  • Description of applications in immunological techniques.
  • Focus on immunoassays for detecting soluble TRAIL.

Main Results:

  • Identification and categorization of various monoclonal antibodies against TRAIL.
  • Demonstration of their effectiveness in immunological assays.
  • Elucidation of TRAIL's role in physiological processes through antibody-based studies.

Conclusions:

  • Monoclonal antibodies against TRAIL are essential reagents for both research and potential therapeutic strategies.
  • These antibodies facilitate the detection and study of soluble TRAIL, contributing to our understanding of its involvement in cancer and inflammatory diseases.
  • Further investigation using these antibodies is crucial for fully understanding TRAIL's physiological significance.

More Related Videos

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants10:44

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...